A Phase 1b PK/PD Study to Demonstrate Antigen Elimination with RLYB212, a Monoclonal Anti-HPA-1a Antibody for FNAIT Prevention.

Autor: Geisen C; Institute of Transfusion Medicine and Immunohaematology, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen GmbH, Frankfurt am Main, Germany., Fleck E; Institute of Transfusion Medicine and Immunohaematology, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen GmbH, Frankfurt am Main, Germany., Schäfer SMG; Division Clinical Research, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany., Walter C; Division Clinical Research, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany., Braeuninger S; Institute of Transfusion Medicine and Immunohaematology, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen GmbH, Frankfurt am Main, Germany., Jensen JS; Aixial Danmark A/S, Herlev, Denmark., Sheridan D; Rallybio, New Haven, Connecticut, United States., Patki K; Rallybio, New Haven, Connecticut, United States., Armstrong R; Rallybio, New Haven, Connecticut, United States., Skogen B; Department of Laboratory Medicine, University Hospital of North Norway, Tromsø, Norway., Behrens F; Division Clinical Research, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany.; Division of Rheumatology, University Hospital Goethe-University Frankfurt am Main, Germany.; Fraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD, Frankfurt am Main, Germany., Seifried E; Institute of Transfusion Medicine and Immunohaematology, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen GmbH, Frankfurt am Main, Germany., Kjeldsen-Kragh J; Department of Laboratory Medicine, University Hospital of North Norway, Tromsø, Norway.; Department of Clinical Immunology and Transfusion Medicine, Office for Medical Services, Region Skåne, Lund, Sweden., Kjær M; Faculty of Health Sciences, UiT-The Arctic University of Norway, Hammerfest, Norway.; Finnmark Hospital Trust, Hammerfest, Norway., Köhm M; Division Clinical Research, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany.; Division of Rheumatology, University Hospital Goethe-University Frankfurt am Main, Germany.; Fraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD, Frankfurt am Main, Germany.

Publikováno v: Thrombosis and haemostasis [Thromb Haemost] 2024 Sep 12. Date of Electronic Publication: 2024 Sep 12.

OC 02.1 Dose-Dependent Elimination of HPA-1a Platelets by Subcutaneous RLYB212, a Monoclonal Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia

Autor: Geisen, C., Fleck, E., Gastón Schäfer, S., Walter, C., Braeuninger, S., Søndergaard Jensen, J., Armstrong, R., Sheridan, D., Patki, K., Kjaer, M., Behrens, F., Seifried, E., Kjeldsen-Kragh, J., Köhm, M.

Publikováno v: In Research and Practice in Thrombosis and Haemostasis October 2023 7 Supplement 2

Screening for fetal and neonatal alloimmune thrombocytopenia: is it possible and what are the potential outcomes?

Autor: Kjeldsen‐Kragh, J.¹ jkk@ppas.no

Publikováno v: ISBT Science Series. May2018, Vol. 13 Issue 2, p187-193. 7p.

Dataset of smart heat and water meter data with accompanying building characteristics.

Autor: Schaffer M; Department of the Built Environment, Aalborg University, Aalborg, Denmark., Veit M; Department of the Built Environment, Aalborg University, Aalborg, Denmark., Marszal-Pomianowska A; Department of the Built Environment, Aalborg University, Aalborg, Denmark., Frandsen M; Department of the Built Environment, Aalborg University, Aalborg, Denmark., Pomianowski MZ; Department of the Built Environment, Aalborg University, Aalborg, Denmark., Dichmann E; Department of the Built Environment, Aalborg University, Copenhagen, Denmark., Sørensen CG; Department of the Built Environment, Aalborg University, Copenhagen, Denmark., Kragh J; Department of the Built Environment, Aalborg University, Copenhagen, Denmark.

Publikováno v: Data in brief [Data Brief] 2023 Dec 15; Vol. 52, pp. 109964. Date of Electronic Publication: 2023 Dec 15 (Print Publication: 2024).

Pregnant Women at Low Risk of Having a Child with Fetal and Neonatal Alloimmune Thrombocytopenia Do Not Require Treatment with Intravenous Immunoglobulin.

Autor: Kjeldsen-Kragh J; Department of Clinical Immunology and Transfusion Medicine, University and Regional Laboratories, Akutgatan 8, 221 85 Lund, Sweden.; Department of Laboratory Medicine, University Hospital of North Norway, 9019 Tromsø, Norway., Bein G; Institute for Clinical Immunology, Transfusion Medicine and Hemostasis, Justus-Liebig-University, 35392 Giessen, Germany.; German Center for Feto-Maternal Incompatibility, University Hospital Giessen and Marburg, Campus Giessen, 35392 Giessen, Germany., Tiller H; Department of Obstetrics and Gynecology, University Hospital of North Norway, 9019 Tromsø, Norway.; Women's Health and Perinatology Research Group, Department of Clinical Medicine, UiT The Arctic University of Norway, 9019 Tromsø, Norway.

Publikováno v: Journal of clinical medicine [J Clin Med] 2023 Aug 24; Vol. 12 (17). Date of Electronic Publication: 2023 Aug 24.